Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Mar 29;104(7):1071-8.
doi: 10.1038/bjc.2011.86. Epub 2011 Mar 15.

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

H J Stemmler  1 , D diGioia, W Freier, H W Tessen, G Gitsch, W Jonat, W Brugger, E Kettner, W Abenhardt, H Tesch, H J Hurtz, S Rösel, O Brudler, V Heinemann
Affiliations
Clinical Trial

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer

H J Stemmler et al. Br J Cancer. .

Abstract

Background: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory.

Methods: Anthracycline-pretreated patients were randomly assigned to three gemcitabine-based regimens. Chemotherapy consisted of gemcitabine 1.000 mg m(-2) plus vinorelbin 25 mg m(-2) on days 1+8 (GemVin), or plus cisplatin 30 mg m(-2) on days 1+8 (GemCis), or plus capecitabine 650 mg m(-2) b.i.d. orally days 1-14 (GemCap), q3w. The primary end point was response rate.

Results: A total of 141 patients were recruited on the trial. The overall response rates were 39.0% (GemVin), 47.7% (GemCis) and 34.7% (GemCap). Median progression-free survival was estimated with 5.7, 6.9 and 8.3 months, respectively. Corresponding median survival times were 17.5 (GemVin), 13.0 (GemCis) and 19.4 months (GemCap). Neutropenia ≥grade 3 occurred in 16.7% (Gem/Vin), 4.4% (GemCis) and 0% (Gem/Cap), whereas non-haematological toxicities were rarely severe except grade 3 hand-foot syndrome in 2.0% of the GemCap patients (per patient analysis).

Conclusions: This randomised phase II trial has revealed comparable results for three gemcitabine-based regimens regarding treatment efficacy and toxicity. Gemcitabine-based chemotherapy appears to be a worthwhile treatment option for pretreated patients with metastatic breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow of participants.
Figure 2
Figure 2
Progression-free survival.
Figure 3
Figure 3
Overall survival.
See this image and copyright information in PMC

References

    1. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P (2001) Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 61: 8723–8729 - PubMed
    1. Ahn JH, Kim SB, Kim TW, Ahn SH, Kim SM, Park JM, Lee JS, Kang YK, Kim WK (2004) Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19: 547–553 - PMC - PubMed
    1. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147–159 - PubMed
    1. Alauddin A, Shaharyar A (2005) Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer. J Clin Oncol, ASCO Annu Meeting Proc (Post-Meeting Edition) 23: abstract 713
    1. Andres R, Mayordomo JI, Lara R, Lastra R, Ortega E, Polo E, Lambea J, Isla D, Saenz-Cusi A, Escudero P, Tres A (2005) Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 6: 158–162 - PubMed

Publication types

MeSH terms